<DOC>
	<DOCNO>NCT01185353</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy LY3009104 participant Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Participants With Rheumatoid Arthritis Background Methotrexate Therapy</brief_title>
	<detailed_description>This study consist follow : - Screening period : 4 28-days - Part A : 12-week blind , placebo control treatment period - Part B : 12-week blinded extension period - Part C : optional 52-week open-label extension period - Part D : additional optional 52-week open-label extension period - Follow period : 28 day</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Must active RA Must regularly use methotrexate ( MTX ) least 12 week participation study Must ACR functional class I , II , III Must Creactive protein ( CRP ) measurement &gt; 1.2 time upper limit normal ( ULN ) Erythrocyte Sedimentation Rate ( ESR ) &gt; upper limit normal ( 28 mm/hr ) Have laboratory value opinion investigator pose unacceptable risk participant study drug would administer Must venous access sufficient allow blood sample per protocol Must reliable willing available duration study willing follow study procedure Must able read , understand , give write informed consent approve Lilly designee ethical review board ( ERB ) govern site Male participant : agree use two form highly effective method birth control female partner childbearing potential study If woman could become pregnant study , must talk study doctor birth control . You require use two form highly effective method birth control avoid get pregnant study If post menopausal woman , must least 45 year age menstruate last 12 month If woman 40 45 year age , test negative pregnancy , menstruate last 12 month , must additional blood test see participate For participant receive corticosteroid , must dose exceed 10 mg prednisone daily ( equivalent ) dose regimen least 6 week prior randomization Continue meet inclusion criterion Parts A B applicable Have complete 52 week ( Week 24 Week 76 ) participation Part C study without permanent study drug discontinuation complete FollowUp Visit ( approximately 28 day last dose study drug ) Must receive parenteral corticosteroid administer intraarticular , intramuscular , intravenous ( IV ) injection Must concomitantly use nonsteroidal antiinflammatory drug ( NSAIDS ) , unless stable dose within last 4 week Must receive prior biologic disease modify antirheumatic drug ( DMARD ) therapy ( TNFÎ± , IL1 , IL6 , Tcell Bcell target therapy ) Must use DMARDs methotrexate ( MTX ) , hydroxychloroquine , sulfasalazine within last 8 week Must use leflunomide within last 12 week receive cholestyramine speed elimination leflunomide body Must previously randomize , complete withdrawn study study investigate LY3009104 Must receive prior treatment oral Janus Kinase ( JAK ) inhibitor Must current recent ( within last 30 day ) viral , bacterial , fungal , parasitic infection Must serious infection ( example , pneumonia , cellulitis , bone joint infection ) atypical mycobacterial infection within last 6 month Must symptomatic herpes zoster herpes simplex infection within last 90 day history disseminated/complicated herpes zoster Must evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody Must evidence hepatitis C virus ( HCV ) active hepatitis B Must evidence suspicion active latent tuberculosis ( TB ) Must another serious disorder illness Must expose live vaccine within last 12 week Must donate 500 mL blood within last month Must surgery joint assess study within last 2 month , require study Must currently enrol , discontinue within last 30 day clinical trial involve investigational drug device offlabel use drug , concurrently enrol type medical research judge scientifically medically compatible study Presence significant uncontrolled cerebracardiovascular ( eg , myocardial infarction ( MI ) , unstable angina , unstable arterial hypertension , severe heart failure cerebrovascular accident ) , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic neuropsychiatric disorder , abnormal laboratory value opinion investigator pose unacceptable risk participant study drug would administer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
</DOC>